Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...

Antiepileptic Drugs: Calcium Channel Blockers

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of long-term exposure to ocean acidification on the Patagonian scallop Zygochlamys patagonica (P.P. king, 1832), a strategic fishery resource in the Southwest Atlantic ocean.

Marine environmental research·2026

Same author

Late-onset epilepsy as a prodromal symptom.

Revue neurologique·2025

Same author

The revolution has begun.

Revue neurologique·2025

Same author

Sex-related variability of white matter tracts in the whole HCP cohort.

Brain structure & function·2024

Same author

Discriminating factors in access to video-EEG for epilepsy surgery in a French tertiary epilepsy center.

Revue neurologique·2024

Same author

Epileptic seizures in patients with primary central nervous system lymphoma: A systematic review.

Revue neurologique·2023

Same journal

Sleep quality and arousal in migraine and tension-type headache: the headache-sleep study.

Acta neurologica Scandinavica. Supplementum·2014

Same journal

Diffusion-weighted lesions in acute ischaemic stroke patients with migraine.

Acta neurologica Scandinavica. Supplementum·2014

Same journal

Mild stroke: safety and outcome in patients receiving thrombolysis.

Acta neurologica Scandinavica. Supplementum·2014

Same journal

MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.

Acta neurologica Scandinavica. Supplementum·2014

Same journal

Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries.

Acta neurologica Scandinavica. Supplementum·2014

Same journal

Advances in genetic diagnosis of neurological disorders.

Acta neurologica Scandinavica. Supplementum·2014

See all related articles

Search research articles

Related Experiment Video

Updated: May 17, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Zonisamide in clinical practice.

S Dupont¹, H Stefan

¹Unité d’Epilepsie, Clinique Neurologique Paul Castaigne, Hôpital de la Salpêtrière, 47 Boulevard de l’Hôpital, Paris Cedex 13, France. sophie.dupont@psl.aphp.fr

Acta Neurologica Scandinavica. Supplementum

|October 31, 2012

Summary

This summary is machine-generated.

Real-world studies show zonisamide is an effective adjunctive treatment for epilepsy, offering a favorable safety profile. Many patients experience reduced seizure frequency or become seizure-free with this antiepileptic drug.

More Related Videos

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

Related Experiment Videos

Last Updated: May 17, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

Area of Science:

Neurology
Clinical Pharmacology

Background:

Zonisamide is approved for partial seizures and epilepsy based on clinical trials.
Real-world data is needed due to diverse patient populations and individualized treatment in clinical practice.

Purpose of the Study:

To evaluate the real-world effectiveness and tolerability of zonisamide in epilepsy management.
To assess zonisamide's performance in routine clinical settings beyond controlled trials.

Main Methods:

Analysis of data from clinical practice studies and the Zonisamid im Alltag Der Epilepsiepatienten (ZADE) study.
Inclusion of diverse patient populations with varying clinical characteristics and tailored treatment approaches.

Main Results:

Adjunctive zonisamide demonstrated effectiveness in real-world settings, mirroring clinical trial findings.
Nearly 80% of patients in the ZADE study achieved ≥50% seizure reduction; over a third became seizure-free.
Zonisamide showed a favorable safety/tolerability profile, high retention rates, and improved quality of life.

Conclusions:

Real-world evidence supports zonisamide's efficacy and tolerability for epilepsy treatment.
Zonisamide provides pragmatic insights into benefits and risks in everyday clinical practice.
Data complements clinical trial findings, offering valuable information for patient management.